NHF's research grants support a variety of disciplines and levels of expertise.
The two recommendations address gene therapy clinical trials, and use of emicizumab-kxwh.
This chapter includes new product approvals and Guelcher explains that ITI could be the solution to eradicate the inhibitor itself.
UniQure recently announced initial clinical data from patients treated in an open-label phase IIb dose-confirmation study of AMT-061, the company’s investigational gene therapy treatment for patients with severe and moderately severe hemophilia B.
NHF, Impact Education and the Postgraduate Institute for Medicine offers accredited educational opportunties for healthcare providers on managing and treating females with bleeding disorders.
Stacy E. Croteau, MD, MMS, pediatric hematologist and clinical researcher at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shares her thoughts on 'the now and the next' in bleeding disorders treatment.
HANDI hopes that you find these pain management resources helpful as we approach the busy holiday season!
CSL Behring is experiencing intermittent supply delays of Mononine®, the company’s human plasma derived factor IX product for treatment of patients with hemophilia B.
The Genentech therapy has been approved for routine prophylaxis in adults and children with or without factor VIII inhibitors.
The National Hemophilia Foundation (NHF) is pleased to announce the 2018 NHF-Shire Clinical Fellowship award recipients.